X4 Pharmaceuticals

Next week we will participate in a fireside chat at the Piper Sandler Healthcare Conference in New York City. We're looking forward to continuing conversations about our clinical progress, including sharing our recent positive results from the Phase 2 study of mavorixafor in chronic neutropenia. Learn about X4's attendance and how to register for our webcast here: https://bit.ly/4g2najI #chronicneutropenia #immunodeficiency

Catch up with us at #ASH24! From December 7-10 we’ll be in San Diego connecting with physicians and other members of the #hematology community, sharing information on our approved treatment for #WHIMsyndrome and our ongoing clinical trial in #chronicneutropenia — come meet with us at booth #2106 to learn more. ? #immunodeficiency #classicalheme ? American Society of Hematology

We're grateful for organizations like the National Neutropenia Network?that provide education and resources for patients living with #chronicneutropenia and their families. ? As we advance our ongoing clinical trial in chronic #neutropenia, we express our thanks to the National Neutropenia Network and look forward to continuing to collaborate with these dedicated advocates. Check out their website to learn more: https://lnkd.in/gqkZfQcD

At this week’s?Leap HR:?Emerging Biopharma conference, our Vice President, People?Pauline Dufresne?presented on the role that culture plays as biotech companies evolve from exclusively R&D-focused into fully-integrated, commercial organizations – a transition we underwent this year with the launch of our first FDA approved therapy. ? Pauline highlighted the importance of strong company culture during times of rapid change and provided insights on how to support patient-centric teams through the launch of a commercial product.? ? #EmergingBiopharma #HR #Biotechnology

On Monday, November 18 we will participate in a fireside chat at the Stifel Financial Corp. Healthcare Conference in New York City. Following our positive results from the Phase 2 study of mavorixafor in chronic neutropenia, we're excited to share our clinical progress. Learn more about the event and how to register here: https://bit.ly/3O6ZZJ1 #chronicneutropenia #immunodeficiency

We’re pleased to announce positive results from our completed Phase 2 study of mavorixafor in chronic neutropenia (CN). Oral mavorixafor durably and meaningfully increased absolute neutrophil counts and led to reduced use of the current standard of care. There has not been a new treatment option for people with CN in almost 30 years and we are encouraged by these data, as we advance our ongoing pivotal Phase 3 trial of mavorixafor in this patient population. Learn more in today’s release: https://bit.ly/4eJj7YJ #chronicneutropenia #clinicaltrial #raredisease

All of us at X4 have a passion for science and creating a better future for those living with #immunodeficiencies. On National #STEM Day we’re celebrating careers in science – a field that can improve lives and transform how our world functions. This past summer, our Project Onramp internship program gave us the chance to immerse a group of talented students within diverse roles at X4. We can’t wait for more opportunities to welcome new faces to #biotech! #NationalSTEMDay

Gaby and Willow are sisters living with WHIM syndrome, a rare immunodeficiency that marked their childhood with frequent infections, absences from school, fatigue and feelings of isolation.? ? After eventually getting the results a genetic test, Gaby and Willow were diagnosed with WHIM syndrome and began treatment. Awareness and understanding of immunodeficiencies such as WHIM are critical to helping individuals like Gaby and Willow.?? ? Learn more directly from them: https://bit.ly/4em4I49?? ? And you can view more stories on our website: https://bit.ly/4fabmvS?? ? #WHIMsyndrome #genetictesting #raredisease #immunodeficiency

Our #X4tizens definitely have the Halloween spirit. Check out the fantastic costumes the team wore to our annual party celebrating the spooky holiday!

During the parallel #ESID2024 and #IPOPI #GPM2024 meetings we engaged with medical, scientific and patient advocacy partners from across the global #immunodeficiency community. At both events we enjoyed fostering new collaborations and learning from each other, all with the shared goal of serving patients.? ? At ESID, we enjoyed sharing more about our Phase 3 4WARD trial in chronic #neutropenia and hearing updates from multiple IEI (inborn errors of immunity) registries around the world. At IPOPI we had the privilege of sitting down with representatives of the international advocacy community to listen to their needs and hopes, and exchange ideas on how to improve awareness, diagnosis and treatment of #immunodeficiencies. Thank you to everyone who came together with us! European Society for Immunodeficiencies (ESID) IPOPI - International Patient Organisation for Primary Immunodeficiencies